TuHURA Biosciences, Inc. (HURA)
| Market Cap | 122.99M +0.3% |
| Revenue (ttm) | n/a |
| Net Income | -30.63M |
| EPS | -0.54 |
| Shares Out | 63.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 524,065 |
| Open | 2.050 |
| Previous Close | 2.060 |
| Day's Range | 1.850 - 2.050 |
| 52-Week Range | 0.410 - 3.430 |
| Beta | -0.84 |
| Analysts | Buy |
| Price Target | 8.04 (+316.58%) |
| Est. Earnings | Nov 13, 2026 |
About HURA
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for HURA stock is "Buy." The 12-month stock price target is $8.04, which is an increase of 316.58% from the latest price.
News
TuHURA Biosciences Transcript: Study update
Three initial patients with deep-seated metastatic MCC had confirmed responses sustained through week 24 after IFx-2.0 plus checkpoint therapy; no serious adverse events were reported across four treated patients. The 9–12-patient study is intended to inform feasibility, safety and potential FDA discussions.
TuHURA Biosciences Press release: Study update
TuHURA Biosciences issued a press release on October 26, 2026, disclosing material business information to investors.
TuHURA Biosciences reports initial data from study of IFx-2.0
TuHURA Biosciences (HURA) announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment of metastatic Merkel Cell...
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ET TAMPA, Fla., Oct. 26, 2026 /PRNewswire...
TuHURA Biosciences granted U.S. patent broadening coverage for VISTA Inhibitor
TuHURA Biosciences (HURA) announced that the USPTO has issued a patent which provides coverage for TBS-2025, TuHURA’s VISTA inhibiting antibody, as well as antigen-binding fragments, modifications to ...
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies TAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHUR...
TuHURA Biosciences receives U.S. patent for DOR ADC technology
TuHURA Biosciences (HURA) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled, “Delta Opioid Receptor Antagonists Reprogram Immunosuppresive Mic...
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosci...
TuHURA Biosciences: FDA clears IND for TBS-2025 VISTA-inhibiting antibody
TuHURA Biosciences (HURA) announced that the U.S. FDA has given clearance to TuHURA’s Investigational New Drug application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of...
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance t...
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Transcript: AGM 2026
The meeting covered director elections, share issuance, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and the Board's recommended three-year frequency for compensation votes was adopted.
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Earnings release: Q2 2026
TuHURA Biosciences released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
TuHURA Biosciences Quarterly report: Q2 2026
TuHURA Biosciences has published its Q2 2026 quarterly earnings report on August 14, 2026.
TuHURA Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing a phase III trial for frontline Merkel cell carcinoma with FDA support, targeting accelerated approval and leveraging novel immunotherapy platforms. Additional programs include a VISTA-inhibiting antibody for AML and innovative ADCs, with key data and regulatory milestones expected within the next year.
TuHURA Biosciences Slides: Corporate presentation
TuHURA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
TuHURA Biosciences Slides: Corporate presentation
TuHURA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Proxy statement: Proxy filing
TuHURA Biosciences filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.
TuHURA Biosciences Proxy statement: Proxy filing
TuHURA Biosciences filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.
TuHURA Biosciences Proxy statement: Proxy filing
TuHURA Biosciences filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
TuHURA Biosciences files IND application with FDA for study of TBS-2025
TuHURA Biosciences (HURA) announced that it has filed an Investigational New Drug application with the U.S. FDA for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of…
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myel...
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...